Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group-Reference-Cited by-同舟云学术

Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group

Published:2020-05-14 Issue:3 Volume:191 Page:405-417
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Rochau Ursula¹^ORCID,Stojkov Igor¹,Conrads‐Frank Annette¹,Borba Helena H.²,Koinig Karin A.³^ORCID,Arvandi Marjan¹,Marrewijk Corine⁴,Garelius Hege⁵,Germing Ulrich⁶,Symeonidis Argiris⁷,Sanz Guillermo F.⁸⁹,Fenaux Pierre¹⁰^ORCID,Witte Theo¹¹,Efficace Fabio¹²,Siebert Uwe¹¹³¹⁴^ORCID,Stauder Reinhard³^ORCID

Affiliation:

1. Department of Public Health, Health Services Research and Health Technology Assessment Institute of Public Health, Medical Decision Making and Health Technology Assessment UMIT – University for Health Sciences, Medical Informatics and Technology Hall i.T. Austria

2. Department of Pharmacy Pharmaceutical Sciences Postgraduate Research Program Federal University of Paraná Curitiba Brazil

3. Department of Internal Medicine V (Hematology and Oncology) Innsbruck Medical University Innsbruck Austria

4. Department of Hematology Radboud university medical center Nijmegen the Netherlands

5. Department of Medicine Section of Hematology and Coagulation Sahlgrenska University Hospital Göteborg Sweden

6. Department of Hematology, Oncology and Clinical Immunology Universitätsklinik Düsseldorf Düsseldorf Germany

7. Department of Internal Medicine Division of Hematology University of Patras Medical School Patras Greece

8. Department of Hematology Hospital Universitario y Politécnico La Fe Valencia Spain

9. Centro de Investigación Biomédica en Red de Cáncer CIBERONC Instituto de Salud Carlos III Madrid Spain

10. Service d'Hématologie Hôpital Saint‐Louis Assistance Publique des Hôpitaux de Paris (AP‐HP) and Université Paris 7 Paris France

11. Department of Tumor Immunology ‐ Nijmegen Center for Molecular Life Sciences Radboud university medical center Nijmegen the Netherlands

12. Health Outcomes Research Unit Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Rome Italy

13. Center for Health Decision Science Department of Health Policy and Management Harvard T.H. Chan School of Public Health Boston MA USA

14. Institute for Technology Assessment and Department of Radiology Massachusetts General Hospital Harvard Medical School Boston MA USA

Funder

Novartis

Amgen

Celgene

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16654

Reference61 articles.

1. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

2. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

3. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

4. Report of an international working group to standardize response criteria for myelodysplastic syndromes;Cheson BD;Blood,2000

5. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MDS patient registries - achievements and challenges;Annals of Hematology;2024-08-23

3. Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG);Journal of Geriatric Oncology;2023-09

5. Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study;Blood Advances;2023-06-15